Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.Oncotarget|February 21, 2020
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertibWayne D Blosser, Jack A Dempsey, Ann M McNulty, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.Nature Communications|March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human studyYonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.Pageof 2